1. Home
  2. AMWD vs CGEM Comparison

AMWD vs CGEM Comparison

Compare AMWD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$39.92

Market Cap

872.8M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$12.81

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWD
CGEM
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
794.7M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
AMWD
CGEM
Price
$39.92
$12.81
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$63.50
$30.11
AVG Volume (30 Days)
227.3K
702.8K
Earning Date
02-26-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,709,585,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$79.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.51
$5.68
52 Week High
$72.16
$16.74

Technical Indicators

Market Signals
Indicator
AMWD
CGEM
Relative Strength Index (RSI) 32.52 41.37
Support Level N/A $11.43
Resistance Level $58.01 $13.21
Average True Range (ATR) 1.76 0.86
MACD -0.05 -0.37
Stochastic Oscillator 33.35 7.32

Price Performance

Historical Comparison
AMWD
CGEM

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: